THE WELINK.CARE LABEL HAS BEEN AWARDED TO



ON THE 6TH OF NOVEMBER 2020 WITH THE VERY HIGH DISRUPTION SCORE OF 91 %



Dr. Thierry Vermeeren, CEO

The WeLink.Care label uses a composite index scoring the disruption value of a digital solution use case in the daily health practice. Our expert team has reviewed the preselected digital solution with a set of 35 points of measure, based on interviews, documents research and analysis.

MOOVCARE RECEIVES THE WELINK.CARE LABEL

Introduction

Moovcare[®] has been awarded the WeLink.Care Label, recognizing its transformative impact on lung cancer patient follow-up. By leveraging weekly patient-reported outcomes to detect symptoms of recurrence early, Moovcare[®] improves survival rates and enhances the quality of care. This distinction reflects Moovcare's clinical rigor, user-centered design, and its potential to redefine post-therapeutic surveillance for lung cancer patients globally.

About the WeLink.Care Label

The WeLink.Care Label was created to identify and promote digital health solutions that demonstrate exceptional potential to disrupt healthcare practices positively. Since its inception during the COVID-19 pandemic, it has served as a benchmark for innovation, evaluating solutions based on their ability to improve care delivery, patient outcomes, and healthcare efficiency.

Awarded only after a rigorous scientific evaluation, the WeLink.Care Label is a mark of excellence, ensuring that solutions like Moovcare[®] meet high standards of evidence, usability, and relevance. The label bridges the gap between cutting-edge technology and practical healthcare applications, providing stakeholders with confidence in adopting solutions that enhance both clinical and patient experiences.

The Evaluation Process

The WeLink.Care evaluation process is a thorough and structured methodology designed to assess the disruptive potential of digital health solutions. It begins with a comprehensive review of available documentation, including scientific studies, market data, and technical specifications. This foundational step ensures evaluators have a complete understanding of the solution's design, purpose, and clinical effectiveness.

Interviews with stakeholders—including solution developers, healthcare professionals, and patients—follow the initial review. These discussions provide invaluable insights into real-world usage, offering a nuanced understanding of the solution's strengths and opportunities for improvement. By integrating diverse perspectives, the process ensures a balanced and practical assessment.

The methodology includes a detailed scoring system that evaluates solutions across five critical dimensions: Business Model, Solution Maturity, Change in Practices, Professional User Experience, and Patient User Experience. Each dimension comprises specific criteria that provide granular insights into how well the solution addresses healthcare challenges and user needs.

Finally, the results are presented in two formats: the Scorecard and the Impact Study. The Scorecard provides a succinct, number-based evaluation, offering a quick overview of the solution's potential. The Impact Study delves deeper, providing a detailed analysis of each dimension, supported by evidence and case studies. This dual approach equips decision-makers with the tools they need to assess and implement transformative healthcare solutions confidently.



MOOVCARE

Introduction to the company

Founded in 2014, Sivan Innovation is a Franco-Israeli company specializing in digital health solutions designed to improve patient outcomes and streamline care practices. The company was built upon the visionary work of Dr. Fabrice Denis, a French oncologist whose innovative approach to patient monitoring through digital tools laid the foundation for Moovcare[®]. Sivan Innovation blends clinical expertise with advanced technology to create solutions that are both scientifically validated and user-friendly. With a commitment to transforming cancer care, Sivan Innovation collaborates with leading institutions, including renowned hospitals like Institut Curie and CHU Lille. The company's flagship product, Moovcare[®], has garnered recognition for its clinical rigor and proven ability to enhance survival rates for lung cancer patients. Sivan continues to innovate and expand its portfolio, driving advancements in digital health with a focus on patient-centric design.

The Solution

Moovcare[®] is a groundbreaking digital therapeutic solution tailored for lung cancer patients. By leveraging weekly patient-reported outcomes through a simple, dynamic questionnaire, Moovcare[®] detects early signs of recurrence or complications, enabling timely medical intervention. This proactive approach bridges the gap between routine follow-up consultations, empowering both patients and healthcare providers to act quickly and effectively. The solution has demonstrated its effectiveness in improving survival rates, with clinical trials showing that Moovcare[®] users live an average of 8 months longer than those under standard surveillance protocols. Designed to seamlessly integrate into existing care pathways, Moovcare[®] reduces the burden of unnecessary hospital visits and provides reassurance to patients through continuous, unobtrusive monitoring.

Features and Benefits

Moovcare[®] combines simplicity with advanced technology, offering two intuitive interfaces: a patient-facing questionnaire and a dashboard for healthcare providers. Patients complete a weekly 12-item questionnaire that evaluates key symptoms such as fatigue, appetite, and shortness of breath. An intelligent algorithm analyzes responses over time, identifying patterns that may indicate a recurrence or complication and alerting the attending physician immediately. The solution delivers multiple benefits, including improved quality of life and reduced anxiety for patients. For healthcare providers, Moovcare[®] streamlines consultations by providing a comprehensive view of the patient's condition through the dashboard, enabling more personalized and efficient care. The system also optimizes resource allocation by reducing unnecessary imaging and hospitalizations, resulting in significant cost savings for healthcare systems.


Compliance and Future Outlook

Moovcare[®] is fully compliant with stringent regulatory requirements, holding a CE Class I certification with plans to upgrade to Class IIa. Patient data is securely stored in certified health data hosting facilities, ensuring adherence to GDPR and other data protection standards. As Sivan Innovation continues to refine Moovcare[®], future developments include expanding its use to other cancer types and geographical markets, including Germany and the United States. By maintaining its focus on clinical validation and adaptability, Moovcare[®] is well-positioned to lead the evolution of digital therapeutics in oncology.

WeLink.Care

DISRUPTION SCORE

The disruption potential of Moovcare[®] is very high, revolutionizing lung cancer follow-up with its innovative digital monitoring. Using weekly patient-reported outcomes analyzed by an intelligent algorithm, Moovcare[®] detects symptoms of recurrence earlier, improving survival rates by nearly 8 months compared to traditional methods. Clinically validated and nationally reimbursed in France, the solution reassures patients and optimizes healthcare delivery. Adopted by leading hospitals and oncologists, Moovcare[®] exemplifies transformative impact in oncology care.





BUSINESS MODEL


Moovcare[®] stands out as the first digital solution in France to secure national reimbursement, with a negotiated price of $\leq 1,000$ per patient per semester. Launched commercially in September 2020, Sivan Innovation forecasts significant growth, aiming for a ≤ 65 million turnover in Europe by 2025, alongside plans for U.S. expansion. Privately funded and debt-free, the company's strong financial foundation supports its ambitious trajectory, positioning Moovcare[®] as a leader in digital health innovation.

BUSINESS MODEL



|~ first profits ~|


BUSINESS PERFORMANCE



WeLink.Care

SOLUTION MATURITY


Moovcare[®] has demonstrated exceptional clinical maturity, with studies showing significant survival benefits, leading to early adoption by the control group during trials. Recognized by the French High Authority for Health (HAS) with a Level 3 Expected Service Improvement (ASA), the solution exemplifies evidence-based innovation. Ongoing clinical research aims to further validate its medico-economic efficiency and expand its applications to other cancer types, reinforcing Moovcare[®] as a leader in digital therapeutics.





CHANGE OF PRACTICES


Moovcare[®] transforms care practices by enhancing the quality of consultations through weekly patient-reported data. This proactive approach enables physicians to better prepare for appointments, tailoring discussions to the patient's evolving condition. Its intelligent algorithm triggers timely alerts for abnormal developments, ensuring rapid responses from the care team. By optimizing care pathways and improving patient management, Moovcare[®] empowers healthcare providers to deliver more effective, personalized, and efficient oncology follow-up.





USER EXPERIENCE : THE PROFESSIONAL AND PATIENT PERSPECTIVE

Moovcare[®] delivers an intuitive user experience for both physicians and patients. Doctors benefit from clear, synthesized views of patient-reported outcomes and evolution curves, enabling more efficient, well-prepared consultations. For patients, the weekly monitoring reduces anxiety by fostering a sense of continuous care. While the system facilitates regular, easy tracking of health parameters, offering patients a retrospective view of their transmitted data could further enhance engagement and understanding of their health progress.



LINKS AND RESOURCES

https://www.moovcare.com/fr/

https://label.welink.care/

This report is based on the information provided by the scored company, input from various stakeholders, and the application of the WeLink.Care[©] methodology by OZConsulting. The findings, scores, and evaluations presented are intended solely for informational purposes and do not constitute a guarantee or endorsement of the quality, effectiveness, or commercial viability of the evaluated digital health solution.

The conclusions are drawn from the data available at the time of the study and may not reflect subsequent changes. OZConsulting assumes no responsibility for the accuracy or completeness of the information provided by the scored company or any third parties involved. Any reliance on this report is at the reader's own risk.

The content of this report is protected under copyright law. No part of this report may be reproduced, distributed, or used for commercial purposes without prior written permission from OZC. The WeLink.Care[©] methodology and scoring system are proprietary to OZConsulting.